Drugs that contain Zanubrutinib

1. Drug name - BRUKINSA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9447106 BEIGENE Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators
Apr, 2034

(11 years from now)

US10570139 BEIGENE Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators
Apr, 2034

(11 years from now)

US11142528 BEIGENE Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators
Apr, 2034

(11 years from now)

US10927117 BEIGENE Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
Aug, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 14, 2024
Orphan Drug Exclusivity (ODE) Sep 14, 2028
New Indication (I) Sep 14, 2024

Market Authorisation Date: 14 November, 2019

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
80MG CAPSULE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.